Skip to main content
Premium Trial:

Request an Annual Quote

Gene By Gene to Support MD Anderson Genomics Education Program

NEW YORK (GenomeWeb News) – Houston-based genomics and genetics testing firm Gene By Gene has inked an agreement with the University of Texas MD Anderson Cancer Center to become one if its affiliated clinical labs, the company said today.

Gene By Gene said that, under the agreement, scientists at its Genomic Research Center will provide clinical phase instruction, training, and supervision for MD Anderson's Molecular Genetic Technology Program, which is one of the undergraduate education programs at the MD Anderson School of Health Professions.

The MD Anderson program is a three-semester course that integrates lectures, lab demonstrations, and technical experience to prepare students for national certification as a molecular genetic technologist.

The program includes courses in medical genetics; clinical applications of molecular biology; molecular diagnosis of genetic disorders and hematological malignancies; advanced molecular diagnostics techniques; independent study special topics, and others.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.